Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ACP1 | P24666 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.48 |
| ▸ | RHOC | P08134 | 5/20 | 0.46 |
| ▸ | RHOA | P61586 | 5/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263685 | 0.87 | LMNA (0.65) | NNMTLMNAACP1ALDH1A1TACR1 | |
| SCHEMBL782086 | 0.84 | GAA (0.56) | LMNAALDH1A1MAPT | |
| SCHEMBL22832993 | 0.84 | KMT2A (0.54) | LMNAALDH1A1MAPT | |
| SCHEMBL22075943 | 0.83 | RHOC (0.60) | NNMTLMNAACP1ALDH1A1TACR1 | |
| SCHEMBL4013181 | 0.81 | LMNA (0.54) | NNMTLMNAACP1ALDH1A1TACR1 | |
| SCHEMBL22387603 | 0.80 | MAPT (0.53) | NNMTLMNAACP1ALDH1A1TACR1 | |
| SCHEMBL25797243 | 0.80 | LMNA (0.53) | NNMTLMNAACP1ALDH1A1TACR1 | |
| SCHEMBL3529269 | 0.80 | GPR35 (0.53) | LMNAALDH1A1TACR1GPR35AKR1C3 | |
| SCHEMBL5950455 | 0.78 | MAPT (0.62) | LMNAACP1TACR1GPR35AKR1C3 | |
| SCHEMBL24554571 | 0.77 | AKR1C3 (0.55) | LMNAGPR35AKR1C3AKR1C2P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-25 | — | — | US | disclosed |
| US-20240123078-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | VIVIDION THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-4045050-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | The Scripps Research Institute (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4045043-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | Vividion Therapeutics, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076703-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | VIVIDION THERAPEUTICS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076755-A1 | AN ACTIVITY-GUIDE MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076755-A1 | AN ACTIVITY-GUIDE MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | THE SCRIPPS RESEARCH INSTITUTE | 2021-01-07 | — | — | US | disclosed |
| US-20200292555-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2020-09-17 | — | — | US | disclosed |
| US-10670605-B2 | Cysteine reactive probes and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-02 | — | — | US | disclosed |
| US-10670605-B2 | Cysteine reactive probes and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190216893-A1 | COMPOSITIONS AND METHODS OF MODULATING IMMUNE RESPONSE | THE SCRIPPS RESEARCH INSTITUTE | 2019-07-18 | — | — | US | disclosed |
| US-20190216893-A1 | COMPOSITIONS AND METHODS OF MODULATING IMMUNE RESPONSE | THE SCRIPPS RESEARCH INSTITUTE | 2019-07-18 | — | — | US | disclosed |
| EP-3365686-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | The Scripps Research Institute (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017205972-A1 | SYSTEMS METHODS AND COMPOSITIONS FOR PREDICTING METASTASIS IN BLADDER CANCER | GENOMEDX BIOSCIENCES, INC. (CA) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017070611-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170115303-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-20170115303-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| WO-2017070611-A1 | CYSTEINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | NNMT 2005/4885LMNA 1798/4885ACP1 1014/4885 |
| US-20240123078-A1 | COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS | CD4, ICOS, NFATC1 | NNMT 2701/4885LMNA 4512/4885ACP1 1310/4885 |
| US-20190216893-A1 | COMPOSITIONS AND METHODS OF MODULATING IMMUNE RESPONSE | IFNG, MYD88, ICOS | NNMT 3078/4885LMNA 4208/4885ACP1 1911/4885 |
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | GSTK1, GSTA2, GSTA1 | NNMT 799/4885LMNA 4748/4885ACP1 2674/4885 |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | NNMT 2005/4885LMNA 1798/4885ACP1 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.